Sentiment Trading

AbbVie Inc. has partnered with Gubra to develop a promising obesity treatment, GUBamy, marking a strategic leap in the obesity treatment arena and potentially bolstering AbbVie’s portfolio and market position.

AbbVie Inc. reported strong Q1 financials, with 8.4% revenue growth and a 16.6% increase in immunology segment revenues, leading to a raised annual profit outlook.